Prescient Therapeutics Collaborates with Carina Biotech for Development of Next Generation CAR-T Therapies

  • Nov 19, 2019 AEDT
  • Team Kalkine
Prescient Therapeutics Collaborates with Carina Biotech for Development of Next Generation CAR-T Therapies

Prescient Therapeutics Limited (ASX: PTX) is a clinical-stage oncology company which is engaged in small molecule drug development focused on new cancer drugs.

The company is known for having a robust clinical pipeline with two drug candidates, PTX 100 and PTX 200, which are under clinical development. Prescient Therapeutics is conducting clinical trials at the world-renowned US cancer centres.

Collaboration with Carina Biotech

The company recently unveiled its collaboration with, Adelaide based, Carina Biotech which is engaged in the production of CAR-T therapy.

With this collaboration, both companies will work on the development of new targeted cell therapies for cancer patients who have solid tumors. Prescient’s expertise, in the development of targeted therapies, will be combined with CAR-T technologies of Carina to develop CAR-T combination therapies for the treatment of a range of solid cancers.

The work will be managed within PTX’s existing budget, and it would not require any additional capital. It is also mentioned that both the companies would equally share any resulting intellectual property (IP) from the alliance. The exact terms of the agreement and collaboration are not disclosed in this announcement.

Chimeric Antigen Receptor T (CAR-T) cell therapy is an innovative and ground-breaking technology in which patients T cells are removed, re-engineered and again introduced back to the body to target and attack cancer cells.

CAR-T cell (or Chimeric Antigen Receptor T cell) therapy technique has been used to outstanding effect against certain blood cancers (particularly B cell malignancies), but to date has been less effective against other hematological and solid cancers. Many solid cancers have proven notoriously difficult to breach using immunotherapies like checkpoint inhibitors, yet account for the majority of cancers diagnosed, presenting an area of particular unmet medical need.

Prescient’s Managing Director and CEO Steven Yatomi-Clarke said in regard to this agreement that Prescient is pleased to have this collaboration opportunity with Carina, working together to develop new CAR-T technologies. Mr Yatomi-Clarke also added that collaboration with Carina boosts on the company’s knowledge of biochemical pathways, and targeted therapies. He also mentioned that it would be an exciting new frontier for the company:

Managing Director of Carina Biotech Dr Justin Coombs commented on this collaboration and said that the early pre-clinical study results from Carina’s CAR T-cells targeting solid tumours have been very positive and the company is actively exploring various approaches for enhancing the response rates in solid tumors.

He also added

Dr Justin Coombs mentioned that business development in immunotherapy is actively increasing and the companies are in the race for developing favorable targeted cancer immune therapies. Further, he added that working together with Prescient will accelerate the process of identifying potential innovative cancer therapies.

This collaboration with Carina will be structured on Prescient’s in-house development expertise with CSO Professor Said Sebti, who is named by Nature as one of the top 20 translational researchers globally, and other efficient team members having extensive experience in innovative oncology therapies and bringing new technologies with leading multinational companies such as GSK, Array, BioPharma and Pfizer.

Phase 1b Clinical Trial for First-in-Class anti-Cancer drug (PTX-100)-

On 14 November 2019 Prescient announced that the first patient had been administered with its second targeted anti-cancer drug (PTX-100), in a Phase 1b clinical trial, currently underway, for Prescient’s first-in-class cancer therapy. The first dose is administered to multiple myeloma patient who had completed 7 days PTX-100 therapy without any significant drug-related side effects.

On 19 November 2019, Prescient's stock was trading at $0.056 up by 12 per cent as compared to its previous closing price, with a market capitilisation of $19.71 million (AEST: 1:51 PM). PTX has 394.26 million outstanding shares trading on ASX.

To know more about Prescient Therapeutics Limited, click here.


Disclaimer

This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. The above article is sponsored but NOT a solicitation or recommendation to buy, sell or hold the stock of the company (or companies) under discussion. We are neither licensed nor qualified to provide investment advice through this platform.

 

All pictures are copyright to their respective owner(s).Kalkinemedia.com does not claim ownership of any of the pictures displayed on this website unless stated otherwise. Some of the images used on this website are taken from the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image.

 

There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.

Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.

As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.

CLICK HERE FOR YOUR FREE REPORT!
   
x
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK